Safety and efficacy of pimecrolimus versus vehicle for the treatment of atopic dermatitis in adults and paediatric population: a systematic review and meta-analysis
Authors:
- Sareema E. AkhtarSASareema E. Akhtar
- Saad ShakilSSSaad Shakil
- Sabeeh K. FarooquiSFSabeeh K. Farooqui
- Tarek KhedroTKTarek Khedro
- Ahmad L. AlzufairiAAAhmad L. Alzufairi
- Muhammad A. NiazMNMuhammad A. Niaz
- Saifullah SyedSSSaifullah Syed
- Riaz JiffryRJRiaz Jiffry
- Abdulla K. AlsubaiAAAbdulla K. Alsubai
- Abdullah AlmesriAAAbdullah Almesri
- Hebatalla IsmailHIHebatalla Ismail
- Kashif A. KhanKKKashif A. Khan
Open Access
- 22 May 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (7) , 3563-3573
Abstract
Introduction: Atopic dermatitis remains a widespread problem affecting various populations globally. While numerous treatment options have been employed, pimecrolimus remains a potent and viable option. Recently, there has been increasing interest in comparing the safety and efficacy of pimecrolimus with its vehicle. Methods: The authors conducted a comprehensive search of several databases, including PubMed, COCHRANE, MEDLINE, and Cochrane Central, from inception to May 2022, using a wide search strategy with Boolean operators. The authors also employed backward snowballing to identify any studies missed in the initial search. The authors included randomized controlled trials in our meta-analysis and extracted data from the identified studies. The authors used Review Manager (RevMan) Version 5.4 to analyze the data, selecting a random-effects model due to observed differences in study populations and settings. The authors considered a P-value of 0.05 or lower to be statistically significant. Results: The authors initially identified 211 studies, of which 13 randomized controlled trials involving 4180 participants were selected for analysis. Our pooled analysis revealed that pimecrolimus 1% was more effective at reducing the severity of atopic dermatitis than its vehicles. However, no significant difference was observed in adverse effects between pimecrolimus and vehicle, except for pyrexia, nasopharyngitis, and headache, which were increased with pimecrolimus. Conclusion: Our meta-analysis showed that pimecrolimus 1% is more effective than vehicle, although the safety profile remains inconclusive. Pimecrolimus reduced the Investigator’s Global Assessment score, Eczema Area and Severity Index score, and severity of pruritus when compared to its vehicle, indicating a higher efficacy profile. This is one of the first meta-analyses to assess the efficacy and safety profile of pimecrolimus 1% against a vehicle and may assist physicians in making informed decisions.Keywords
This publication has 31 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Topical use of pimecrolimus in atopic dermatitis: Update on the safety and efficacyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009
- Effectiveness and safety of a prevention‐of‐flare‐progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2008
- Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic DermatitisPediatric Dermatology, 2008
- Relapsing lichen actinicus successfully treated with cyclosporinJournal of the European Academy of Dermatology and Venereology, 2007
- A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroidsBritish Journal of Dermatology, 2007
- Influence of Pimecrolimus Cream 1% on Different Morphological Signs of Eczema in Infants with Atopic DermatitisDermatology, 2004
- Long-Term Efficacy and Safety of Pimecrolimus Cream 1% in Adults with Moderate Atopic DermatitisDermatology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitisJournal of the American Academy of Dermatology, 1987